HEALTHSENS is developing a very useful rapid test for the specific and early diagnosis of myocardial infarction. Thanks to this self-diagnostic test, patients will be able to quickly know whether or not they are suffering from a heart attack, since many times their symptoms can be confused with other conditions, such as a panic attack or anxiety crises.
The rapid determination of troponin at an early stage from the onset of pain allows to accelerate the diagnosis to achieve a more effective treatment.
HEALTHSENS TROPOSTRIP® will consist of a side-flow strip that works similar to the one used for the pregnancy or Covid-19 test and is able to detect, in a drop of blood, a protein called cardiac troponin I, Specific biomarker of myocardial infarction, which is released into the bloodstream when heart damage occurs.
Cardiac troponin consists of three subunits (troponin I, C, T), with subunit I having the greatest clinical interest. This subunit is specifically associated with myocardial infarction and coronary/arterial disease. The determination of troponin I, in conjunction with the clinical evaluation of the patient, is used to stratify the risk of suffering a heart attack or coronary/arterial disease in people who present with chest pain or symptoms of cardiovascular disease.
HEALTHSENS TROPOSTRIP®’s design will be of the “barcode” type, with different cut-off values for different troponin I concentrations, quickly providing a semi-quantitative result based on the relationship between the number of test lines appearing on the strip and the analyte concentration. In this way, it will be possible to estimate the concentration of troponin I in the blood, so that, if it is high, go quickly to a health center and save life.
Today, the available trials used to measure cardiac troponin I, while providing an adequate diagnosis, present several drawbacks. Some of these are the need for specialized personnel to take a venous blood sample and its subsequent analysis through laborious laboratory techniques using voluminous devices. These tools are also very expensive and require constant maintenance. A device such as HEALTHSENS TROPOSTRIP® will reduce costs from the outset and can easily be used not only in modern clinics and hospitals, but also in the most disadvantaged contexts (rural or isolated areas, developing countries, war zones, etc.) as it is a practical device, chemically stable and able to provide the patient with an accurate result in record time compared to the conventional clinical methodologies used for the determination of troponin I.
HEALTHSENS TROPOSTRIP® is a very practical device and can be carried in a simple pocket thanks to its small size, in addition to being able to provide very significant clinical information in a matter of minutes.
The biomarker cardiac troponin I is highly specific for myocardial infarction.
Cardiovascular disease is currently the leading cause of death globally.
Ischemic heart disease and heart attacks account for 16 per cent and 11 per cent of annual deaths worldwide, respectively.
In 2019, 8.9 million deaths were due to ischemic heart disease.